Cancer/Tumor Profiling Market Set to Reach USD 27 Billion by 2030, Driven by Rising Cancer Incidence and Technological Advancements
According to Next Move Strategy Consulting, global Cancer/Tumor Profiling Market, is poised for robust growth, with projections to reach USD 27 billion by 2030, reflecting a compound annual growth rate (CAGR) of 12% from 2024 to 2030. This growth is propelled by the increasing prevalence of cancer worldwide, significant advancements in molecular diagnostic tools, and the expanding application of artificial intelligence (AI) in tumor profiling technologies.
Download Free Sample: https://www.nextmsc.com/cancer-tumor-profiling-market/request-sample
Cancer or tumor profiling involves analyzing the genetic and molecular characteristics of cancer cells, enabling personalized treatment plans and targeted therapies. This innovative approach is a key component of precision medicine, offering insights into genetic mutations, alterations, and molecular features that are critical for diagnosis and therapy development. Technologies such as next-generation sequencing (NGS), immunoassays, and mass spectrometry are leading the charge in transforming cancer care, allowing for more effective treatments and improved patient outcomes.
Rising Cancer Incidence Fuels Market Growth
The rising global incidence of cancer is a major driver for the cancer profiling market. According to the World Health Organization (WHO), cancer was responsible for approximately 10 million deaths in 2020, with cervical cancer alone contributing to over 600,000 new cases and 342,000 deaths annually. The growing cases of human papillomavirus (HPV)-related cancers further emphasize the need for advanced diagnostic and profiling tools that can provide personalized treatment strategies, thereby driving market demand.
Government and International Initiatives Boost Market Dynamics
Government bodies and international organizations are also playing a significant role in advancing the cancer profiling market. Notable initiatives, such as the 'HPV VAX NOW' campaign by the U.S. Department of Health and Human Services and Australia’s USD 15 million investment in the Australian Centre for Targeted Therapeutics, are fostering the adoption of advanced cancer diagnostic tools. These efforts not only aim to reduce cancer incidence but also underscore the importance of precision oncology, which relies heavily on comprehensive tumor profiling.
Moreover, Europe’s substantial investment in cancer research, as seen in the Beating Cancer Plan with over USD 4.53 billion in funding, will accelerate the development and application of advanced profiling technologies across the region.
Inquire Before Buying: https://www.nextmsc.com/cancer-tumor-profiling-market/inquire-before-buying
High Costs and Economic Challenges
Despite the positive market outlook, one of the major challenges to market growth is the high cost associated with cancer profiling technologies. The need for sophisticated equipment, specialized reagents, and highly trained professionals creates financial barriers, particularly in regions with limited healthcare budgets. These high costs can limit the accessibility and adoption of tumor profiling, restricting its potential reach.
AI Integration Presents New Opportunities
The integration of Artificial Intelligence (AI) in cancer profiling technologies is creating new growth opportunities. AI-driven tools for real-time monitoring, data analysis, and treatment adjustments are transforming cancer diagnostics. For instance, Roche’s AI-based algorithms for breast cancer imaging are indicative of the growing trend of using AI to enhance the accuracy and efficiency of tumor profiling.
Regional Insights
North America currently holds the largest share of the Cancer/Tumor Profiling market and is expected to maintain its dominant position throughout the forecast period. The region's high cancer incidence rates, combined with the presence of major industry players like Caris Life Sciences, Thermo Fisher Scientific, and Guardant Health, drive the demand for advanced tumor profiling solutions. In particular, strategic collaborations such as the partnership between Pfizer and Thermo Fisher Scientific to expand access to next-generation sequencing-based testing are expected to further fuel market growth.
Europe is also experiencing substantial growth in the cancer profiling market, driven by increased governmental funding and research initiatives focused on combating cancer. The rising cancer burden, particularly among the European Union member states, and the funding of initiatives like the Beating Cancer Plan are helping propel the adoption of advanced profiling technologies in the region.
Competitive Landscape
The Cancer/Tumor Profiling market is highly competitive, with key players such as Lucence Health Inc., F. Hoffmann-La Roche Ltd, Caris Life Sciences, ACT Genomics, Thermo Fisher Scientific Inc., and Guardant Health at the forefront of innovation. These companies are focusing on collaborations, product launches, and the development of next-generation profiling solutions to maintain their market leadership. For example, Lucence Health Inc. introduced its multi-cancer early detection (MCED) blood test, LucenceINSIGHT, while Roche launched the AVENIO Tumour Tissue Comprehensive Genomic Profiling Kit to enhance local tumor analysis.
Conclusion
The Cancer/Tumor Profiling Market is experiencing significant growth, driven by the rising incidence of cancer, increased government and organizational initiatives, advancements in technology, and the integration of AI. However, challenges such as high costs remain a barrier to widespread adoption. The market is expected to continue evolving, with technological advancements and strategic partnerships paving the way for more accessible and personalized cancer treatments.
Also, Browse Related Reports:
For more information, please contact:
Next Move Strategy Consulting
E-Mail: info@nextmsc.com
Direct: +1-217-650-7991
Website: www.nextmsc.com
Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube
About Next Move Strategy Consulting:
Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.